195 related articles for article (PubMed ID: 34706549)
21. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
22. Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study.
Kostopoulou E; Kalavrizioti D; Davoulou P; Sinopidis X; Papachristou E; Goumenos DS; Dimitriou G; Spiliotis BE; Papasotiriou M
Eur J Pediatr; 2024 May; 183(5):2383-2389. PubMed ID: 38448612
[TBL] [Abstract][Full Text] [Related]
23. Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease.
Ismail A; Hayek SS
Curr Cardiol Rep; 2023 Dec; 25(12):1797-1810. PubMed ID: 37948017
[TBL] [Abstract][Full Text] [Related]
24. Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.
Weidemann DK; Abraham AG; Roem JL; Furth SL; Warady BA
Am J Kidney Dis; 2020 Aug; 76(2):194-202. PubMed ID: 31987488
[TBL] [Abstract][Full Text] [Related]
25. Soluble urokinase plasminogen activator receptor is associated with cardiovascular calcification in peritoneal dialysis patients.
Guan J; Gong S; He Q; Wang X; Shen S; Wu X; Shan J; Gong T; Yang Y; Xie H
Int Urol Nephrol; 2024 Jan; 56(1):191-198. PubMed ID: 37195572
[TBL] [Abstract][Full Text] [Related]
26. Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
Nikorowitsch J; Borchardt T; Appelbaum S; Ojeda F; Lackner KJ; Schnabel RB; Blankenberg S; Zeller T; Karakas M
J Am Heart Assoc; 2020 Apr; 9(8):e015452. PubMed ID: 32299288
[TBL] [Abstract][Full Text] [Related]
27. Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study.
Schutte AE; Myburgh A; Olsen MH; Eugen-Olsen J; Schutte R
Thromb Res; 2012 Aug; 130(2):273-7. PubMed ID: 22113150
[TBL] [Abstract][Full Text] [Related]
28. Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes.
Peiró ÓM; Cediel G; Bonet G; Rojas S; Quintern V; Carrasquer A; González-Del-Hoyo M; Sanz E; Bardají A
Biomarkers; 2020 Jul; 25(5):402-409. PubMed ID: 32551985
[No Abstract] [Full Text] [Related]
29. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
Jhee JH; Nam BY; Lee CJ; Park JT; Han SH; Kang SW; Park S; Yoo TH
J Am Heart Assoc; 2021 Jan; 10(1):e017225. PubMed ID: 33325248
[TBL] [Abstract][Full Text] [Related]
30. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
Persson M; Östling G; Smith G; Hamrefors V; Melander O; Hedblad B; Engström G
Stroke; 2014 Jan; 45(1):18-23. PubMed ID: 24253546
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
[TBL] [Abstract][Full Text] [Related]
32. Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19.
Luo S; Vasbinder A; Du-Fay-de-Lavallaz JM; Gomez JMD; Suboc T; Anderson E; Tekumulla A; Shadid H; Berlin H; Pan M; Azam TU; Khaleel I; Padalia K; Meloche C; O'Hayer P; Catalan T; Blakely P; Launius C; Amadi KM; Pop-Busui R; Loosen SH; Chalkias A; Tacke F; Giamarellos-Bourboulis EJ; Altintas I; Eugen-Olsen J; Williams KA; Volgman AS; Reiser J; Hayek SS;
J Am Heart Assoc; 2022 Sep; 11(18):e025198. PubMed ID: 35924778
[TBL] [Abstract][Full Text] [Related]
33. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
[TBL] [Abstract][Full Text] [Related]
34. Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor (suPAR) levels.
Isola G; Polizzi A; Alibrandi A; Williams RC; Leonardi R
J Periodontol; 2021 Jun; 92(6):896-906. PubMed ID: 33091149
[TBL] [Abstract][Full Text] [Related]
35. Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population.
Haupt TH; Kallemose T; Ladelund S; Rasmussen LJ; Thorball CW; Andersen O; Pisinger C; Eugen-Olsen J
Biomark Insights; 2014; 9():91-100. PubMed ID: 25574132
[TBL] [Abstract][Full Text] [Related]
36. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
[TBL] [Abstract][Full Text] [Related]
37. Long term pronostic value of suPAR in chronic heart failure: reclassification of patients with low MAGGIC score.
Dupuy AM; Kuster N; Bargnoux AS; Aguilhon S; Huet F; Leclercq F; Pasquié JL; Roubille F; Cristol JP
Clin Chem Lab Med; 2021 Jun; 59(7):1299-1306. PubMed ID: 33544524
[TBL] [Abstract][Full Text] [Related]
38. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.
Rasmussen LJ; Knudsen A; Katzenstein TL; Gerstoft J; Obel N; Jørgensen NR; Kronborg G; Benfield T; Kjaer A; Eugen-Olsen J; Lebech AM
HIV Med; 2016 May; 17(5):350-7. PubMed ID: 26365671
[TBL] [Abstract][Full Text] [Related]
39. Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
Fagerberg B; Borné Y; Barregard L; Sallsten G; Forsgard N; Hedblad B; Persson M; Engström G
Environ Res; 2017 Jan; 152():185-191. PubMed ID: 27792942
[TBL] [Abstract][Full Text] [Related]
40. Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure.
Koller L; Stojkovic S; Richter B; Sulzgruber P; Potolidis C; Liebhart F; Mörtl D; Berger R; Goliasch G; Wojta J; Hülsmann M; Niessner A
JACC Heart Fail; 2017 Apr; 5(4):268-277. PubMed ID: 28359415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
